Full Breakdown
Noubar Afeyan Warns of Backlash Against Science in the U.S.
1/12/2026, 8:09:37 PM
The Core Warning: Threats to U.S. Biotech Innovation
In a recent letter, Noubar Afeyan, co-founder of Moderna and CEO of Flagship Pioneering, expressed grave concerns about the current state of scientific inquiry and innovation in the United States. He warned that actions taken by the Trump administration in 2025, which included significant funding cuts and policy changes affecting agencies like the FDA and the National Institutes of Health, could severely undermine the foundations of American science and biotechnology. Afeyan characterized these actions as a "sledgehammer" to the scientific method, potentially endangering U.S. life expectancy and allowing countries like China to gain a competitive edge in biotech.
Background: The Erosion of Scientific Support
Afeyan's letter, issued at the J.P. Morgan Healthcare Conference, highlighted a troubling trend of skepticism towards established scientific practices. He noted that this skepticism has morphed into a pervasive doubt regarding the scientific method itself, which is essential for generating reliable medical advancements. He cited the resurgence of measles as a direct consequence of policy decisions that have turned away from decades of scientific consensus on vaccination.
Key Figures: Noubar Afeyan
Noubar Afeyan is a prominent figure in the biotech industry, having founded numerous companies and played a pivotal role in the development of innovative therapies. His insights reflect a deep concern for the future of medical research and public health in the U.S., particularly in light of recent governmental actions that he believes threaten scientific rigor.
The Impact of Policy Decisions
Afeyan pointed to specific examples of how recent policy changes have jeopardized public health. He noted that the U.S. has seen a significant increase in measles cases, a disease previously eliminated, due to declining vaccination rates. He emphasized that these trends are not random but are the result of deliberate policy choices that disregard scientific evidence.
The Global Context: China's Rise in Biotech
Afeyan also contrasted the U.S. situation with China's aggressive investment in scientific research, which has increased by 400-fold over the past decade. He warned that if the U.S. continues to undermine its scientific foundations, it risks losing its historical lead in biotechnology. He highlighted China's rapid advancements in drug approvals and clinical trials, suggesting that the U.S. could become reliant on foreign innovations for critical medical advancements.
Official Statements & Responses
Afeyan's letter has not yet received a formal response from the Department of Health and Human Services, which has defended its actions as aligned with "gold-standard science." However, Afeyan remains critical, arguing that the current trajectory could lead to the U.S. becoming an "innovation desert," unable to protect its citizens during health crises.
Criticism & Opposition
While Afeyan's views reflect a significant concern within the scientific community, some officials within the Trump administration maintain that their policies are necessary for reforming regulatory frameworks. They argue that these changes will ultimately benefit scientific progress by streamlining processes.
Verbatim Quotes
- “Skepticism is an important part of the scientific method. Debate about approaches and outcomes is central to how science works,” — Noubar Afeyan, CEO of Flagship Pioneering
- “If we lose our ability to collectively resolve our skepticism through the scientific method,” — Noubar Afeyan, CEO of Flagship Pioneering
- “It is the result of choices, policy decisions, to turn our backs on decades of science.” — Noubar Afeyan, CEO of Flagship Pioneering
Afeyan's letter serves as a stark reminder of the potential consequences of undermining scientific integrity and the urgent need for a renewed commitment to evidence-based policy-making in the U.S.
